Drugs / Dual-targeting VEGFR1 and PD-L1 CAR-T cells
Dual-targeting VEGFR1 and PD-L1 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05477927 | Nov 2023 → Dec 2024 | peritoneal carcinomatosis | Sichuan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual-targeting VEGFR1 and PD-L1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05477927 ↗ |
| Modality | Cell therapy | “The VEGFR1/PD-L1 dual-targeting CAR-T will be investigated in cancer patients with serosal cavity metastases.” NCT05477927 ↗ |
| Route | Other | “will be injected in to pleural or peritoneal cavity of patients with advanced serous cavity metastases” NCT05477927 ↗ |